Morgan Stanley Ultragenyx Pharmaceutical Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Morgan Stanley holds 638,879 shares of RARE stock, worth $22 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

638,879

Previous 626,400 1.99%

Holding current value

$22 Million

Previous $22.7 Million 2.42%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$31.06 - $39.3 $387,597 - $490,424	12,479 Added 1.99%	638,879 $23.2 Million
Q1 2025 May 15, 2025	BUY	$36.21 - $45.78 $1.02 Million - $1.29 Million	28,211 Added 4.72%	626,400 $22.7 Million
Q4 2024 Feb 14, 2025	BUY	$42.07 - $57.72 $5.48 Million - $7.52 Million	130,353 Added 27.86%	598,189 $25.2 Million
Q3 2024 May 14, 2025	SELL	$40.21 - $59.36 $1.21 Million - $1.79 Million	-30,133 Reduced 6.05%	467,836 $26 Million
Q3 2024 Nov 14, 2024	SELL	$40.21 - $59.36 $1.21 Million - $1.79 Million	-30,133 Reduced 6.05%	467,836 $26 Million
Q2 2024 May 14, 2025	SELL	$37.42 - $51.61 $3.75 Million - $5.17 Million	-100,220 Reduced 16.75%	497,969 $20.5 Million
Q2 2024 Oct 17, 2024	SELL	$37.42 - $51.61 $239,974 - $330,974	-6,413 Reduced 1.27%	497,969 $20.5 Million
Q2 2024 Aug 14, 2024	SELL	$37.42 - $51.61 $239,974 - $330,974	-6,413 Reduced 1.27%	497,969 $20.5 Million
Q1 2024 Oct 17, 2024	BUY	$43.02 - $53.69 $275,887 - $344,313	6,413 Added 1.29%	504,382 $23.5 Million
Q1 2024 Aug 16, 2024	SELL	$43.02 - $53.69 $4.01 Million - $5 Million	-93,167 Reduced 15.59%	504,382 $23.5 Million
Q1 2024 May 15, 2024	SELL	$43.02 - $53.69 $4.01 Million - $5 Million	-93,167 Reduced 15.59%	504,382 $23.5 Million
Q4 2023 Aug 16, 2024	BUY	$31.73 - $49.19 $3.16 Million - $4.9 Million	99,580 Added 20.0%	597,549 $28.6 Million
Q4 2023 Feb 13, 2024	BUY	$31.73 - $49.19 $3.24 Million - $5.02 Million	102,060 Added 20.6%	597,549 $28.6 Million
Q3 2023 Nov 15, 2023	SELL	$34.92 - $46.66 $757,275 - $1.01 Million	-21,686 Reduced 4.19%	495,489 $17.7 Million
Q2 2023 Aug 14, 2023	BUY	$37.35 - $52.15 $5.93 Million - $8.28 Million	158,765 Added 44.3%	517,175 $23.9 Million
Q1 2023 May 15, 2023	BUY	$36.99 - $48.71 $1.85 Million - $2.44 Million	50,063 Added 16.24%	358,410 $14.4 Million
Q4 2022 Feb 14, 2023	SELL	$33.72 - $46.33 $3.09 Million - $4.25 Million	-91,766 Reduced 22.94%	308,347 $14.3 Million
Q3 2022 Nov 14, 2022	BUY	$39.96 - $66.14 $2.82 Million - $4.66 Million	70,464 Added 21.38%	400,113 $16.6 Million
Q2 2022 Oct 27, 2022	BUY	$45.8 - $85.4 $3.89 Million - $7.25 Million	84,910 Added 34.69%	329,649 $19.7 Million
Q2 2022 Aug 15, 2022	BUY	$45.8 - $85.4 $3.89 Million - $7.25 Million	84,910 Added 34.69%	329,649 $19.7 Million
Q1 2022 Oct 27, 2022	SELL	$62.2 - $84.4 $5.28 Million - $7.17 Million	-84,910 Reduced 25.76%	244,739 $17.8 Million
Q1 2022 May 13, 2022	BUY	$62.2 - $84.4 $3.28 Million - $4.45 Million	52,735 Added 27.47%	244,739 $17.8 Million
Q4 2021 Feb 14, 2022	SELL	$73.71 - $87.86 $2.73 Million - $3.26 Million	-37,065 Reduced 16.18%	192,004 $16.1 Million
Q3 2021 Nov 15, 2021	BUY	$77.92 - $102.4 $17.8 Million - $23.5 Million	229,069 New	229,069 $20.7 Million

Others Institutions Holding RARE

# of Institutions

359

Shares Held

88.2M

Call Options Held

3.64M

Put Options Held

2.24M

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $2.41B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account